Pioneering Cardiovascular Intelligence
ComKardia is building an AI-powered decision-support platform for coronary artery disease (CAD) and PCI planning. By creating a patient-specific digital twin and enabling scenario-based evaluation of treatment approaches, the platform is designed to help interventional cardiologists plan stent strategy—selection, sizing, and placement—with greater precision and consistency.
Integrated into the cath lab workflow
ComKardia is building an AI-powered decision-support platform for coronary artery disease (CAD) and PCI planning. By creating a patient-specific digital twin and enabling scenario-based evaluation of treatment approaches, the platform is designed to help interventional cardiologists plan stent strategy—selection, sizing, and placement—with greater precision and consistency.
Built on deep research and defensible IP
Built on a decade of NIH-funded research and led by a multidisciplinary team spanning interventional cardiology, biomedical engineering, and AI, ComKardia addresses a key adoption barrier: despite the benefits of intravascular imaging, utilization remains limited due to workflow complexity, time burden, and variability in interpretation. Our platform aims to make imaging-guided PCI more practical at scale.
ComKardia holds foundational IP with issued and pending patents across AI algorithms, data integration, and image-guided decision support. The company is exploring strategic collaborations across the interventional ecosystem (including discussions with major device and imaging leaders) and plans to scale through a software licensing and SaaS model, complemented by analytics.
Management Team
Management Team
Management Team
Leadership
Maria Kyparissopoulou
Co-Founder, President & CEO
Maria Kyparissopoulou leads ComKardia, a pioneering med-tech company advancing AI-driven cardiovascular intervention technology. With 15+ years in fundraising and institutional growth, she combines deep business acumen with mission-driven innovation. Holding master’s degrees in Political Science, International Business Management, and Fundraising Management, Maria has guided ComKardia to secure global patents, strategic partnerships (including Boston Scientific), and key milestones toward FDA clearance. She holds master’s degrees in Political Science and International Business Management from Heriot-Watt University in Scotland, as well as a Master’s in Fundraising Management from the Lilly Family School of Philanthropy, equipping her with the expertise to secure substantial funding for groundbreaking ventures.
Maria Kyparissopoulou
Co-Founder, President & CEO
Maria Kyparissopoulou leads ComKardia, a pioneering med-tech company advancing AI-driven cardiovascular intervention technology. With 15+ years in fundraising and institutional growth, she combines deep business acumen with mission-driven innovation. Holding master’s degrees in Political Science, International Business Management, and Fundraising Management, Maria has guided ComKardia to secure global patents, strategic partnerships (including Boston Scientific), and key milestones toward FDA clearance. She holds master’s degrees in Political Science and International Business Management from Heriot-Watt University in Scotland, as well as a Master’s in Fundraising Management from the Lilly Family School of Philanthropy, equipping her with the expertise to secure substantial funding for groundbreaking ventures.
Maria Kyparissopoulou
Co-Founder, President & CEO
Maria Kyparissopoulou leads ComKardia, a pioneering med-tech company advancing AI-driven cardiovascular intervention technology. With 15+ years in fundraising and institutional growth, she combines deep business acumen with mission-driven innovation. Holding master’s degrees in Political Science, International Business Management, and Fundraising Management, Maria has guided ComKardia to secure global patents, strategic partnerships (including Boston Scientific), and key milestones toward FDA clearance. She holds master’s degrees in Political Science and International Business Management from Heriot-Watt University in Scotland, as well as a Master’s in Fundraising Management from the Lilly Family School of Philanthropy, equipping her with the expertise to secure substantial funding for groundbreaking ventures.
Dr. Yiannis Chatzizisis MD, PHD
Dr. Yiannis Chatzizisis MD, PHD
Dr. Yiannis Chatzizisis MD, PHD
Advisory Board
Dr. Pascal J. Goldschmidt MD, FA, FAHA
Chairman of the Advisory Board
Dr. Goldschmidt is an accomplished professor, healthcare administrator, medical researcher and physician (cardiology). He has served as a Tenured Professor at three prestigious institutions, Duke University School of Medicine, Ohio State University (OSU) and University of Miami. He was Center Director at Johns Hopkins then OSU, Chief of Cardiology at OSU then Duke, Chairman of Medicine at Duke, and in 2006 became Dean of the Miller School of Medicine and Founder/CEO of UHealth, the University of Miami Health System.
Dr. Goldschmidt has a long list of honors and awards, beginning in 1980 with his graduation as a medical doctor and Valedictorian of Class of 225 from the Université Libre de Bruxelles.
The list of his patents, publications, articles and abstracts numbers more than 500. His 250 invited lectureships and speaking engagements are testimony to his professional expertise.
Dr. Pascal J. Goldschmidt MD, FA, FAHA
Chairman of the Advisory Board
Dr. Goldschmidt is an accomplished professor, healthcare administrator, medical researcher and physician (cardiology). He has served as a Tenured Professor at three prestigious institutions, Duke University School of Medicine, Ohio State University (OSU) and University of Miami. He was Center Director at Johns Hopkins then OSU, Chief of Cardiology at OSU then Duke, Chairman of Medicine at Duke, and in 2006 became Dean of the Miller School of Medicine and Founder/CEO of UHealth, the University of Miami Health System.
Dr. Goldschmidt has a long list of honors and awards, beginning in 1980 with his graduation as a medical doctor and Valedictorian of Class of 225 from the Université Libre de Bruxelles.
The list of his patents, publications, articles and abstracts numbers more than 500. His 250 invited lectureships and speaking engagements are testimony to his professional expertise.
Dr. Pascal J. Goldschmidt MD, FA, FAHA
Chairman of the Advisory Board
Dr. Goldschmidt is an accomplished professor, healthcare administrator, medical researcher and physician (cardiology). He has served as a Tenured Professor at three prestigious institutions, Duke University School of Medicine, Ohio State University (OSU) and University of Miami. He was Center Director at Johns Hopkins then OSU, Chief of Cardiology at OSU then Duke, Chairman of Medicine at Duke, and in 2006 became Dean of the Miller School of Medicine and Founder/CEO of UHealth, the University of Miami Health System.
Dr. Goldschmidt has a long list of honors and awards, beginning in 1980 with his graduation as a medical doctor and Valedictorian of Class of 225 from the Université Libre de Bruxelles.
The list of his patents, publications, articles and abstracts numbers more than 500. His 250 invited lectureships and speaking engagements are testimony to his professional expertise.
Dr. William O’Neill MD, MSCAI
Advisory Board Member
Dr. O’Neill, is an internationally recognized leader in Interventional Cardiology and Structural Heart Disease, as well as a pioneer in research and new techniques to diagnose and treat heart disease.
Dr. O’Neill is one of the few Master Fellows out of 4,500 world-wide members of the Society for Cardiovascular Angiography and Interventions (MSCAI), the professional medical society for invasive and interventional cardiologists. He pioneered the use of angioplasty for the treatment of heart attacks, which is now the mainstay therapy throughout the world. He has been working on new catheter-based treatments of structural heart disease and performed the first transcaval aortic valve replacement (TAVR) through a catheter in the U.S. in 2005. Currently he is organizing new protocols to treat a deadly side-effect of massive heart attacks, known as the National Cardiogenic Shock Initiative (NCSI). This initiative has proven to increase patient survival rates from 50% to 76%.
A leader in academic and teaching hospitals for nearly 30 years, and to date, an author of more than 300 hundred peer-reviewed articles and abstracts published in medical literature, Dr. O’Neill has written multiple book chapters and edited one of the first textbooks in the field of interventional cardiologists. He was a founding member of the American Board of Internal Medicine interventional cardiology board, which certifies all interventional cardiologists.
Dr. William O’Neill MD, MSCAI
Advisory Board Member
Dr. O’Neill, is an internationally recognized leader in Interventional Cardiology and Structural Heart Disease, as well as a pioneer in research and new techniques to diagnose and treat heart disease.
Dr. O’Neill is one of the few Master Fellows out of 4,500 world-wide members of the Society for Cardiovascular Angiography and Interventions (MSCAI), the professional medical society for invasive and interventional cardiologists. He pioneered the use of angioplasty for the treatment of heart attacks, which is now the mainstay therapy throughout the world. He has been working on new catheter-based treatments of structural heart disease and performed the first transcaval aortic valve replacement (TAVR) through a catheter in the U.S. in 2005. Currently he is organizing new protocols to treat a deadly side-effect of massive heart attacks, known as the National Cardiogenic Shock Initiative (NCSI). This initiative has proven to increase patient survival rates from 50% to 76%.
A leader in academic and teaching hospitals for nearly 30 years, and to date, an author of more than 300 hundred peer-reviewed articles and abstracts published in medical literature, Dr. O’Neill has written multiple book chapters and edited one of the first textbooks in the field of interventional cardiologists. He was a founding member of the American Board of Internal Medicine interventional cardiology board, which certifies all interventional cardiologists.
Dr. William O’Neill MD, MSCAI
Advisory Board Member
Dr. O’Neill, is an internationally recognized leader in Interventional Cardiology and Structural Heart Disease, as well as a pioneer in research and new techniques to diagnose and treat heart disease.
Dr. O’Neill is one of the few Master Fellows out of 4,500 world-wide members of the Society for Cardiovascular Angiography and Interventions (MSCAI), the professional medical society for invasive and interventional cardiologists. He pioneered the use of angioplasty for the treatment of heart attacks, which is now the mainstay therapy throughout the world. He has been working on new catheter-based treatments of structural heart disease and performed the first transcaval aortic valve replacement (TAVR) through a catheter in the U.S. in 2005. Currently he is organizing new protocols to treat a deadly side-effect of massive heart attacks, known as the National Cardiogenic Shock Initiative (NCSI). This initiative has proven to increase patient survival rates from 50% to 76%.
A leader in academic and teaching hospitals for nearly 30 years, and to date, an author of more than 300 hundred peer-reviewed articles and abstracts published in medical literature, Dr. O’Neill has written multiple book chapters and edited one of the first textbooks in the field of interventional cardiologists. He was a founding member of the American Board of Internal Medicine interventional cardiology board, which certifies all interventional cardiologists.
Dr. David E. Kandzari MD, MSCAI
Advisory Board Member
Dr. David E. Kandzari is the Director, Interventional Cardiology and Chief Scientific Officer the Piedmont Heart Institute in Atlanta, Georgia. Dr. Kandzari specializes in cardiovascular disease, peripheral arterial disease and interventional cardiology. A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences.
Dr. Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 200 studies, book chapters and scientific reviews, and has delivered more than 300 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology.
Dr. Kandzari has been voted as one of Atlanta's Top Doctors by Atlanta Magazine in 2011 and 2012, and is peer-nominated in the top 1% of cardiologists by U.S News and World Report.
Dr. David E. Kandzari MD, MSCAI
Advisory Board Member
Dr. David E. Kandzari is the Director, Interventional Cardiology and Chief Scientific Officer the Piedmont Heart Institute in Atlanta, Georgia. Dr. Kandzari specializes in cardiovascular disease, peripheral arterial disease and interventional cardiology. A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences.
Dr. Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 200 studies, book chapters and scientific reviews, and has delivered more than 300 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology.
Dr. Kandzari has been voted as one of Atlanta's Top Doctors by Atlanta Magazine in 2011 and 2012, and is peer-nominated in the top 1% of cardiologists by U.S News and World Report.
Dr. David E. Kandzari MD, MSCAI
Advisory Board Member
Dr. David E. Kandzari is the Director, Interventional Cardiology and Chief Scientific Officer the Piedmont Heart Institute in Atlanta, Georgia. Dr. Kandzari specializes in cardiovascular disease, peripheral arterial disease and interventional cardiology. A graduate of Duke University School of Medicine, he completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences.
Dr. Kandzari is the former Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as Chief Medical Officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a Medical Officer for the Center for Devices and Radiological Health for the United States Food and Drug. Board certified by the American Board of Internal Medicine and its subspecialty Board of Cardiovascular Disease and Board of Interventional Cardiology, Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 200 studies, book chapters and scientific reviews, and has delivered more than 300 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology.
Dr. Kandzari has been voted as one of Atlanta's Top Doctors by Atlanta Magazine in 2011 and 2012, and is peer-nominated in the top 1% of cardiologists by U.S News and World Report.
George Behrakis
Advisory Board Member
George Behrakis is a dynamic strategist, entrepreneur, and thought leader whose work spans policy and politics, innovation and technology, civic engagement, and the arts. He is the Co-Founder and Chief Strategy Officer of the Climate Solutions Fund (CSF), where he works with bipartisan political and policy leaders across the United States to advance market-based climate and energy solutions. In 2022, he was recognized by the Aspen Institute as a Future Climate Leader.
George is also the Principal of G2 Strategies, a boutique consulting firm advising business leaders, philanthropists, and civil society organizations on navigating the rapidly evolving intersection of politics, policy, and business. His advisory work spans the energy, health, biotechnology, and technology sectors, with a focus on helping leaders translate complex policy and regulatory dynamics into actionable strategies.
Deeply engaged in the Greek-American community, George is a Co-Founder of the AXIOS Project, an initiative dedicated to raising awareness of climate impacts in Greece and mobilizing diaspora leadership, investment, and philanthropic capital to address the country’s environmental challenges.
Also a committed advocate for civic education and democratic participation, George became the youngest board member in 2024 of Tufts University’s Jonathan M. Tisch College of Civic Life, the nation’s leading institution focused on advancing the civic engagement of young people.
George holds a B.A. in Economics and Music from Tufts University and an M.A. in Music Composition from the New England Conservatory. He currently divides his time between Boston, Massachusetts, and Athens, Greece.
George Behrakis
Advisory Board Member
George Behrakis is a dynamic strategist, entrepreneur, and thought leader whose work spans policy and politics, innovation and technology, civic engagement, and the arts. He is the Co-Founder and Chief Strategy Officer of the Climate Solutions Fund (CSF), where he works with bipartisan political and policy leaders across the United States to advance market-based climate and energy solutions. In 2022, he was recognized by the Aspen Institute as a Future Climate Leader.
George is also the Principal of G2 Strategies, a boutique consulting firm advising business leaders, philanthropists, and civil society organizations on navigating the rapidly evolving intersection of politics, policy, and business. His advisory work spans the energy, health, biotechnology, and technology sectors, with a focus on helping leaders translate complex policy and regulatory dynamics into actionable strategies.
Deeply engaged in the Greek-American community, George is a Co-Founder of the AXIOS Project, an initiative dedicated to raising awareness of climate impacts in Greece and mobilizing diaspora leadership, investment, and philanthropic capital to address the country’s environmental challenges.
Also a committed advocate for civic education and democratic participation, George became the youngest board member in 2024 of Tufts University’s Jonathan M. Tisch College of Civic Life, the nation’s leading institution focused on advancing the civic engagement of young people.
George holds a B.A. in Economics and Music from Tufts University and an M.A. in Music Composition from the New England Conservatory. He currently divides his time between Boston, Massachusetts, and Athens, Greece.
George Behrakis
Advisory Board Member
George Behrakis is a dynamic strategist, entrepreneur, and thought leader whose work spans policy and politics, innovation and technology, civic engagement, and the arts. He is the Co-Founder and Chief Strategy Officer of the Climate Solutions Fund (CSF), where he works with bipartisan political and policy leaders across the United States to advance market-based climate and energy solutions. In 2022, he was recognized by the Aspen Institute as a Future Climate Leader.
George is also the Principal of G2 Strategies, a boutique consulting firm advising business leaders, philanthropists, and civil society organizations on navigating the rapidly evolving intersection of politics, policy, and business. His advisory work spans the energy, health, biotechnology, and technology sectors, with a focus on helping leaders translate complex policy and regulatory dynamics into actionable strategies.
Deeply engaged in the Greek-American community, George is a Co-Founder of the AXIOS Project, an initiative dedicated to raising awareness of climate impacts in Greece and mobilizing diaspora leadership, investment, and philanthropic capital to address the country’s environmental challenges.
Also a committed advocate for civic education and democratic participation, George became the youngest board member in 2024 of Tufts University’s Jonathan M. Tisch College of Civic Life, the nation’s leading institution focused on advancing the civic engagement of young people.
George holds a B.A. in Economics and Music from Tufts University and an M.A. in Music Composition from the New England Conservatory. He currently divides his time between Boston, Massachusetts, and Athens, Greece.
Operating Advisors
Actively Driving Strategy, Execution, and Growth
ComKardia has partnered with IronStreet Advisors, a premier healthcare-focused advisory firm, to guide the company’s evolution from breakthrough technology to scalable, commercially successful enterprise. The IronStreet team brings a proven track record in healthcare operations, investment, and commercialization — and is deeply engaged as both strategic advisors and active investors in ComKardia’s growth.
Our Operating Advisors are hands-on partners, working alongside ComKardia’s leadership team to refine business strategy, build operational infrastructure, and position the company for rapid market adoption and long-term value creation.